The Treg cell therapy MedTech has raised £ 117 million for a platform aimed at helping transplant patients.
Regulatory T cells are known as “master modulators” of immune homeostasis. Quell Therapeutics are using them to create new cell therapies designed to suppress excessive immune responses, promote long-term resistance in the local immune environment, and promote tissue repair.
Its platform technology allows the company to design, design, and manufacture therapeutic Treg products on a larger scale with greater stability, sustainability, and efficacy than previous generations.
Quell, who finished the Series A round for £ 60m earlier this year, said the Series B round was co-led by founding investor Syncona, along with Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC. rice field.
New investors include the Future Fund: Breakthrough Program, Janus Henderson Investors, Monashee Investment Management, Point72, and British Patient Capital through funds managed by Tekla Capital Management LLC.
The London-based company’s lead program, QEL-001, is designed to prevent organ rejection in liver transplant patients by inducing lasting immune tolerance and eliminating the need for lifelong immunosuppression. It has been.
The clinic is scheduled to enter the clinic in the first half of 2022, and patient recruitment is expected to begin by the end of the year.
This funding will fund the clinical development of QEL-001 in liver transplantation, accelerate the development of product pipelines across transplantation, neuroinflammatory and autoimmune diseases, and enhance the multimodular Treg platform and manufacturing footprint. Used to do.
“Quell is at the forefront of a new wave of cell therapy. We are leading a highly differentiated, multi-modular approach to the engineering and production of Treg therapies,” said CEO Iain McGill. increase.
“We are proud to have the support of this Premier Investor Syndicate as we move forward to the next stage of growth.
“This funding will advance our pipeline and platform, including capital, state-of-the-art science, and world-class teams, to provide treatments that can ultimately transform patients suffering from the disease. It has the full capabilities to achieve major milestones. It is caused by immunodysregulation. “
Rachel Mears (Jeito Capital’s partner), Jeffrey Long-McGie (Ridgeback Capital’s MD), and Houman Ashrafian (SV Health Investors’ managing partner) have joined Quell’s board of directors in connection with funding.
Martin Murphy, CEO of Syncona Investment Management Limited, said: It offers the potential to make a real difference in a patient’s life.
“Since then, the progress of the Quell team, led by Iain McGill, has been remarkable. The business has moved from concept to clinic in less than three years. We look forward to its pioneering lead program entering the clinic this year.
“This funding highlights the progress the company has made and the scale of its ambitions. Backed by a strong syndication of global investors, the business is a leader in innovative new areas of medicine. As we are trying to establish our position, we can advance our lead programs and pipelines while building scalable manufacturing capabilities. “
Quell Raises £ 117m to Support Business Cloud for Liver Transplant Patients
Source link Quell Raises £ 117m to Support Business Cloud for Liver Transplant Patients